Pharma Research Library | Pharma Info Index Research | Innovation | Opportunities |
Swapna Pokkula*1, Santhrani Thaakur2, Lavanya Yaidikar3
1Department of Pharmacology, Browns College of Pharmacy, Khammam, Telangana, India.
2Department of Pharmacology, Sri Padmavathi Mahila Visvavidyalayam, Tirupati, Andhra Pradesh, India.
3Seven Hills College of Pharmacy, Tirupati–517502, Andhra Pradesh, India
A B S T R A C T
Neurodegeneration of the central and peripheral nervous system causes neuropathic pain. The present study has been investigated the attenuating role of Icariin (ICA) against partial sciatic nerve ligation (PSNL) induced peripheral neuropathy in rats. Adult male rats were divided into six groups with six rats in each group and partial ligation was performed on left sciatic nerve in group II to group VI; Sham control, PSNL control, Pregabalin (standard control), ICA 50 mg/kg/p.o, ICA 100 mg/kg/p.o and ICA 100 mg/kg alone (no exposure/ligation) groups. Oral administration of vehicle/pregabalin/ICA was given once daily for 21 consecutive days based on groups. Various nociceptive behavioral parameters were investigated by assessing foot deformity score, motor co-ordination test, cold allodynia, radiant heat hyperalgesia, exploratory behavior and spontaneous locomotor activity which were done on 0th, 7th, 14th and 21st days. Biochemical tests like superoxide dismutase (SOD), calcium (Ca2+), Catalase (CAT), reduced glutathione (GSH), glutathione reductase (GR) and histopathological changes were measured in sciatic nerve homogenate. Treatment with ICA and pregabalin significantly (p<0.001) attenuated the PSNL induced neuropathic pain in dose dependent manner in all nociceptive pain tests and biochemical oxidative stress markers. Therefore, it is concluded that ICA has promising neuroprotective action against PSNL induced neuropathic pain due to its anti-oxidant and anti-nociceptive effects.
Keywords: Icariin, Partial sciatic nerve ligation, Neuropathic Pain
